YUNNAN BAIYAO(000538)2025-01-13 09:28Sales Performance - In the first half of 2024, the sales revenue of Pudilan Anti-inflammatory Tablets exceeded 100 million CNY, achieving nearly double-digit growth year-on-year [2] - The sales revenue of Gongxuening Capsules increased by 36% year-on-year [2] - The health product segment achieved a revenue of 3.144 billion CNY, with a net profit of 1.231 billion CNY, and a net profit growth of 1.7% year-on-year [4] - The sales revenue of Yangyuanqing hair care products reached 195 million CNY, with a growth rate of 41% [4] Marketing and Brand Positioning - The online marketing campaign generated approximately 350 million exposures and 2.96 million interactions, attracting over 1.1 million consumers and achieving a GMV growth of 47% year-on-year [2] - Yunnan Baiyao toothpaste maintained its leading market share in the domestic oral care sector, ranking as the top oral care brand during the "618" shopping festival [4] - Yangyuanqing was recognized as the top brand for anti-hair loss shampoo on Tmall during the "618" period [4] Dividend Distribution - In 2023, Yunnan Baiyao's dividend plan was 20.77 CNY per 10 shares, totaling 3.706 billion CNY, which accounted for 90.53% of the net profit [5] - A special dividend of 12.13 CNY per 10 shares is proposed for 2024, with a total amount of 2.164 billion CNY, representing 50.02% of the net profit for the first three quarters of 2024 [6] Future Development Plans - The provincial pharmaceutical company aims to stabilize revenue growth, enhance risk management, and improve operational efficiency [7] - The overall strategic goal is to achieve growth in revenue, profit, and asset scale through a "2+3" strategy from 2024 to 2028, positioning itself as a leading modern pharmaceutical group [8]